Navigation Links
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, May 2
Date:4/26/2013

SAN DIEGO, April 26, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it will provide a corporate update and discuss first quarter 2013 financial results after the NASDAQ Global Select Market closes on Thursday, May 2, 2013. The conference call and webcast will begin at 5:15 p.m. Eastern Time (2:15 p.m. Pacific Time).

The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' First Quarter 2013 Financial Results Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ® (lorcaserin HCl), Arena's internally discovered drug, is approved in the United States and is under review for regulatory approval in additional territories. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information, visit Arena's website at www.arenapharm.com.

Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the regulatory review of BELVIQ; and Arena's focus, plans, goals, strategy, expectations, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing and supply issues and the pace of market acceptance; cash and revenues generated from BELVIQ, including the impact of competition; Arena's revenues will be based in part on management's estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding Arena's estimates or accounting policies may result in changes to Arena's guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing when expected or ever by any other regulatory agency; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for further research and development, regulatory review or approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law. Contact: Arena Pharmaceuticals, Inc. 

Media Contact: Russo PartnersCindy McGee, Vice President , 

David Schull, PresidentInvestor Relations & Alliance Managementdavid.schull@russopartnersllc.comcmcgee@arenapharm.com  

858.717.2310858.453.7200, ext. 1479 www.arenapharm.com
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
2. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
3. Arena Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
4. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, March 4
5. Proposed Regulatory Uniformity to Boost Venture Capital Investments in Healthcare Arena, Says Frost & Sullivan
6. Arena Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference
7. Arena Pharmaceuticals and Ildong Pharmaceutical Enter Into Co-Development and License Agreement for Temanogrel, a Novel Agent for Thrombotic Diseases
8. Arena Pharmaceuticals to Webcast Live Presentation at the Piper Jaffray 24th Annual Healthcare Conference
9. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
11. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Tuesday, November 6
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016  Redwood Scientific Technologies, Inc. announced ... designed to help women balance their hormones. This product ... Jason Cardiff , President and CEO. ... to help the millions of women across the country ... of imbalanced hormones. Our research and development team is ...
(Date:2/5/2016)... , Feb. 5, 2016  Patients in Alabama ... focused ultrasound (HIFU) therapy no longer have to travel out ... its partnership with Urology Centers of Alabama to ... FDA-cleared procedure for qualifying patients. Alabama ... in the treatment of prostate cancer using many different modalities. ...
(Date:2/5/2016)... 5, 2016  Venice,s newest laser clinic, ... of its kind in the area and specializes ... laser treatment. The physician-owned and operated laser clinic ... by storm with its revitalizing skin care approach, ... Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
Breaking Medicine Technology:
(Date:2/8/2016)... Houma, LA (PRWEB) , ... February 08, 2016 ... ... Louisiana from offices in Houma, LA, celebrates the beginning of a new charity ... raised to assist Court Appointed Special Advocates (CASA). In the belief that children ...
(Date:2/8/2016)... ... , ... If you are feeling that your clothes are a tad snug, ... the Center for Disease Control and Prevention (CDC), 34.9% of U.S. adult women are ... cancer, some of the leading causes of preventable death. February is heart health ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local ... the greater Venice, FL area, has initiated a fundraiser for a two year ... just four days after Christmas. To support this beautiful child who is facing ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... that co-occur frequently. While a significant number of women and men with eating ... the trauma itself, that best predicts the development of an eating disorder. ...
(Date:2/8/2016)... ... February 08, 2016 , ... The ... important news! AHCC and the Home Health and Hospice ICD-10 Transition Workgroup are ... official ICD coding guidance and clarifications, to address concerns over the use of ...
Breaking Medicine News(10 mins):